Filing Details

Accession Number:
0001567619-21-005449
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-02 20:18:07
Reporting Period:
2021-02-26
Accepted Time:
2021-03-02 20:18:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1446847 Ironwood Pharmaceuticals Inc IRWD () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1361754 J Alexander Denner C/o Ironwood Pharmaceuticals, Inc.
100 Summer Street, Suite 2300
Boston MA 02110
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2021-02-26 505,100 $9.20 14,545,100 No 4 P Indirect See Footnote
Class A Common Stock Acquisiton 2021-03-01 344,900 $9.60 14,890,000 No 4 P Indirect See footnote
Class A Common Stock Acquisiton 2021-03-02 500,000 $9.56 15,390,000 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Class A Common Stock 37,844 Direct
Footnotes
  1. Consists of shares that are held by Sarissa Capital Management LP ("Sarissa Capital") or by the funds and other investment vehicles (the "Sarissa Funds") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.